PRIME: EMA Says Yes To Only Three Of Twenty Hopefuls
Executive Summary
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
You may also be interested in...
Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.
Latest Japan Approvals Include World-First For Pabinafusp
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
New Therapeutic Targets & A Rich Year For Approvals: EMA’s PRIME In 2020
Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.